CLINICAL ROLE OF IGFBP-3 IN THE BLOOD SERUM OF PATIENTS WITH BREAST CANCER T1-2N0M0 STAGES

Download full text PDF
Issue: 
6
Year: 
2017

U.R. Mamedov Ph.D. (Med.), Senior Research Scientist, N.N. Blokhin Russian Cancer Research Center (Moscow), O.I. Kostileva Ph.D. (Med.), Senior Research Scientist, N.N. Blokhin Russian Cancer Research Center (Moscow) E-mail: biochimia@yandex.ru , V.D. Ermilova Ph.D. (Med.), Senior Research Scientist, N.N. Blokhin Russian Cancer Research Center (Moscow), A.V. Maslyaev Oncologist, N.N. Blokhin Russian Cancer Research Center (Moscow), I.K. Vorotnikov Ph.D. (Med.), Professor, N.N. Blokhin Russian Cancer Research Center (Moscow)

The content of IGFBP-3 was determined in the blood serum of the 291 patient with breast cancer T1-2N0M0 stages by ELISA before treatment and of 75 healthy women of the control group. The rate of IGFBP-3 was discovered to be significantly elevated in patients with breast cancer T1-2N0M0 stages compared to control. The marker IGFBP-3 did not reflect the stage of breast cancer, was not associated with histological structure of the tumor and also did not reflect receptor status (ER, ER) breast cancer and expression of Her2-neu in the primary tumor. It was revealed that the level of marker IGFBP-3 was significantly lower in the serum of patients with «luminal A» subtype of breast cancer. Despite the fact that serum marker IGFBP-3, investigated in patients with breast cancer T1-2N0M0 stages, reflect certain morphological and biological characteristics of the tumor, it cannot be used in the diagnosis of this disease.

Keywords: 
Key words: IGFBP-3
breast cancer
blood serum.

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.